Last reviewed · How we verify
Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse
A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.
Details
| Lead sponsor | Ulthera, Inc |
|---|---|
| Status | COMPLETED |
| Enrolment | 101 |
| Start date | 2015-04 |
| Completion | 2015-07 |
Conditions
- Skin Laxity
Interventions
- Ultherapy
- Incobotulinumtoxin A
- Radiesse
- Belotero Balance
Primary outcomes
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability — Within 6 months before or after Ultherapy
An assessment of adverse events through chart review will evaluate the safety of combination treatments of Ultherapy with toxins/fillers.
Countries
United States